Kalobios Pharmaceuticals, Inc.

Medarex Inc.

Ludwig Institute for Cancer Research Limited

Beijing University of Technology

Humanigen, Inc.

Engen Bio, Inc.

Coulter Pharmaceutical, Inc.

Monash University

Geoffrey T Yarranton

Christopher Robert Bebbington

Lesley B Pickford

Kenneth Luehrsen

Sanjeev Gangwar

Thomas Jay Lobl

Matthew H Nieder

Mark Baer

Andre Trouet

Vincent Dubois

Varghese Palath

David Martinez

David J King

Christina Yi

Ann Marie Fernandez

Evan Lewis

Howard P Ng

Guoxian Wu

David M Martinez

Oliver L Saunders

Zhihong Li

Jeng-Horng Her

Andrew Ewart Scott

Peter Flynn

Nenad Tomasevic

Valeri Martichonok

Robert F Balint

Martin Lackmann

André Trouet

Andrew Mark Scott

Mark Alfenito

Doris Bucher

Jason Williams

Danny Pc McGee

Kenneth R Luehrsen

Swathi Sujatha-Bhaskar

Carmelina Murone

Catherine To

Thomas J Lobl

Peter Viski

Anne-Marie Fernandez

The invention provides methods for generating human antibodies with the specificity of a reference antibody by replacement of portions of the Vand Vsequences of the reference antibody with sequences from human antibody repertoires. The invention also provides novel compositions comprising hybrid immunoglobulin variable domains containing a combination of frameworks (FRs) and CDRs from different antibody clones.

Immunoglobulin variable region cassette exchange

The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.

Influenza vaccine and therapy

The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.

Antibodies to EphA3

The present invention is directed generally to compositions and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from prokaryotes without the need for a signal peptide through making use of mutant host strains with altered secretory properties. In particular, the invention provides host cells and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from bacteria without the need for a signal peptide and provides diverse libraries of antibody sequence resulting from such methods. The invention additionally provides diverse libraries.

Secretion of antibodies without signal peptides from bacteria

The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders.

Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow

The invention provides anti-EGF-like module containing, mucin-like, hormone receptor-like 1 (EMR1) antibodies and methods of using such antibodies to treat EMR1-related diseases.

Anti-EMR1 antibodies

The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.

Antibodies to granulocyte-macrophage colony-stimulating factor

The current invention provides high-affinity antibodies to thePcrV protein that have reduced immunogenicity when administered to treatinfections.

[object Object]

The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.

Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3

Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 interferon receptor antibody antagonists and fragments thereof, as well as polypeptides and small molecules that inhibit the interaction of type 1 interferon with its receptor (IFNAR).

Methods for the therapy of inflammatory bowel disease using a type-1 interferon antagonist

This invention provides methods of treating patients having ainfection where the patient also has a low level of. The methods comprise administering an antagonist of theType III Secretion System, e.g., an anti-PcrV antibody antagonist.

The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors.

EphA3 antibodies for the treatment of solid tumors

The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody and pharmaceutical compositions comprising such antagonists.

Methods of treating dementia using a GM-CSF antagonist

Growing community of inventors

Burlingame, CA, United States of America

Geoffrey T Yarranton